StreetInsider.com News Articles

MannKind to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:30:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available

MannKind to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:30:00 -0400

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Form 8-K MANNKIND CORP For: Aug 21

Fri, 21 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260821/26961477.html

Form 8-K MANNKIND CORP For: Aug 21

Fri, 21 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260821/26961477.html

Form 424B7 MANNKIND CORP

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961405.html

Form 424B7 MANNKIND CORP

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961405.html

Form SCHEDULE 13G MANNKIND CORP Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930193.html

Form SCHEDULE 13G MANNKIND CORP Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930193.html

Form 4 MANNKIND CORP For: Aug 07 Filed by: Binder Steven B.

Mon, 10 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260810/26899695.html

Form 4 MANNKIND CORP For: Aug 07 Filed by: Binder Steven B.

Mon, 10 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260810/26899695.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 07 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260807/26891739.html

Form 144 MANNKIND CORP Filed by: Binder Steven B.

Fri, 07 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260807/26891739.html

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Thu, 06 Aug 2026 06:57:54 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented: "FDA approval and launch of pediatric Afrezza, FDA approval of FUROSCIX ReadyFlow and clean Phase 1b tolerability data for nintedanib DPI/MNKD-201 in patients with IPF. The focus in 2H26 shifts from regulatory and clinical catalysts to commercial execution. MNKD reported a mixed but thesis-supportive 2Q26, with revenue modestly above consensus, although the composition of the beat was weighted toward manufacturing and collaboration revenue rather than the company’s promoted products. The commercial tailwinds from pediatric Afrezza and FUROSCIX ReadyFlow should become more

MannKind (MNKD) PT Lowered to $13 at Wells Fargo

Thu, 06 Aug 2026 06:38:29 -0400

Wells Fargo analyst Ben Burnett lowered the price target on MannKind (NASDAQ: MNKD) to $13.00 (from $14.00) while maintaining a Overweight rating.

MannKind (MNKD) Reports In-Line Q2 EPS

Wed, 05 Aug 2026 16:47:18 -0400

MannKind (NASDAQ: MNKD) reported Q2 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $109.37 million versus the consensus estimate of $109.02 million.

For earnings history and earnings-related data on MannKind (MNKD) click here.

Form 10-Q MANNKIND CORP For: Jun 30

Wed, 05 Aug 2026 16:07:00 -0400

http://archive.fast-edgar.com/20260805/A52BN22FZW2RH2ZK222A22YOMTPBZZ22Z282

Filed on: August 5, 2026

Form 10-Q MANNKIND CORP For: Jun 30

Wed, 05 Aug 2026 16:07:00 -0400

http://archive.fast-edgar.com/20260805/A52BN22FZW2RH2ZK222A22YOMTPBZZ22Z282

Filed on: August 5, 2026

Form 8-K MANNKIND CORP For: Aug 05

Wed, 05 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26873717.html

Form 8-K MANNKIND CORP For: Aug 05

Wed, 05 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26873717.html

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:01:00 -0400

Achieved three major catalysts to drive future growth:
- Launched the pediatric indication of Afrezza^® following FDA approval
- FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD
- Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement
Encouraging early momentum in Afrezza pediatric launch
- 1 in 3 of the top 100 pediatric insulin writers have prescribed
Q2 2026 total revenues of $109.4M, +43%

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:01:00 -0400

Achieved three major catalysts to drive future growth:
Launched the pediatric indication of Afrezza^® following FDA approval
FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD
Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement

Encouraging early momentum in Afrezza pediatric launch
1 in 3 of the top 100 pediatric insulin writers have prescribed

Q2 2026 total revenues of $109.4M, +43%

Form SCHEDULE 13G MANNKIND CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:47:00 -0400
si-local-file:///var/storage/secattach/20260731/26848469.html

Form SCHEDULE 13G MANNKIND CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:47:00 -0400
si-local-file:///var/storage/secattach/20260731/26848469.html

MannKind (MNKD) PT Raised to $14 at Wells Fargo

Thu, 30 Jul 2026 08:35:18 -0400
Wells Fargo analyst Ben Burnett raised the price target on MannKind (NASDAQ: MNKD) to $14.00 (from $11.00) while maintaining a Overweight rating.

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Thu, 30 Jul 2026 06:52:26 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).
The analyst commented: "We view INFLO-1 as supportive of the nintedanib DPI development program, with the results addressing the near-term question of whether repeated dry-powder administration is tolerated in patients with IPF. The absence of bronchospasm, pulmonary-function changes or treatment discontinuations is encouraging, while the cough observed was generally mild or moderate and transient. Although seven days of treatment cannot establish the expected long-term gastrointestinal or pulmonary tolerability profile, and no efficacy conclusions can be drawn, we view the clean AE profile as a